{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Capsule%28s%29+Once+a+Day+by+Mouth",
    "query": {
      "intervention": "Placebo Capsule(s) Once a Day by Mouth"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T08:38:13.606Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07220694",
      "title": "Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairment and Insulin Resistance",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Insulin Resistance",
        "Mild Cognitive Impairment",
        "Cognitive Decline",
        "Neurodegenerative Disorders"
      ],
      "interventions": [
        {
          "name": "Sabroxy®",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "SF Research Institute, Inc.",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 140,
      "start_date": "2026-01-29",
      "completion_date": "2026-04-29",
      "has_results": false,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-10-05T08:38:13.606Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07220694"
    },
    {
      "nct_id": "NCT05056727",
      "title": "A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Renal Insufficiency, Chronic",
        "Hyperkalemia"
      ],
      "interventions": [
        {
          "name": "Sodium Zirconium Cyclosilicate (SZC)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Lisinopril",
          "type": "DRUG"
        },
        {
          "name": "Valsartan",
          "type": "DRUG"
        },
        {
          "name": "Irbesartan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 1112,
      "start_date": "2021-09-30",
      "completion_date": "2024-02-07",
      "has_results": true,
      "last_update_posted_date": "2026-01-08",
      "last_synced_at": "2026-10-05T08:38:13.606Z",
      "location_count": 42,
      "location_summary": "Surprise, Arizona • Tucson, Arizona • Canyon Country, California + 36 more",
      "locations": [
        {
          "city": "Surprise",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Canyon Country",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05056727"
    },
    {
      "nct_id": "NCT03193398",
      "title": "BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "BTRX-246040 oral capsule(s)",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsule(s)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BlackThorn Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 104,
      "start_date": "2017-06-12",
      "completion_date": "2018-12-12",
      "has_results": true,
      "last_update_posted_date": "2021-05-11",
      "last_synced_at": "2026-10-05T08:38:13.606Z",
      "location_count": 8,
      "location_summary": "Cerritos, California • Garden Grove, California • Jacksonville, Florida + 5 more",
      "locations": [
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Lauderhill",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03193398"
    },
    {
      "nct_id": "NCT02947893",
      "title": "Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Placebo Capsule(s) Once a Day by Mouth",
          "type": "DRUG"
        },
        {
          "name": "Nilotinib Capsule(s) Once a Day by Mouth",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 37,
      "start_date": "2017-01",
      "completion_date": "2021-03",
      "has_results": true,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-10-05T08:38:13.606Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02947893"
    },
    {
      "nct_id": "NCT03095066",
      "title": "Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neurobehavioral Disinhibition"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "AVP-786-28",
          "type": "DRUG"
        },
        {
          "name": "AVP-786-42.63",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 168,
      "start_date": "2017-05-30",
      "completion_date": "2022-08-31",
      "has_results": true,
      "last_update_posted_date": "2025-10-29",
      "last_synced_at": "2026-10-05T08:38:13.606Z",
      "location_count": 54,
      "location_summary": "Tuscaloosa, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 45 more",
      "locations": [
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03095066"
    },
    {
      "nct_id": "NCT01457339",
      "title": "Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "SPD489 (Lisdexamfetamine dimesylate)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 31,
      "start_date": "2011-10-21",
      "completion_date": "2012-01-20",
      "has_results": true,
      "last_update_posted_date": "2021-06-03",
      "last_synced_at": "2026-10-05T08:38:13.606Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Long Beach, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01457339"
    },
    {
      "nct_id": "NCT01106651",
      "title": "A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Canagliflozin 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Canagliflozin 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Antihyperglycemic agent(s)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "55 Years to 80 Years"
      },
      "enrollment_count": 716,
      "start_date": "2010-06",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2014-11-04",
      "last_synced_at": "2026-10-05T08:38:13.606Z",
      "location_count": 34,
      "location_summary": "Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 31 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Carmichael",
          "state": "California"
        },
        {
          "city": "Citrus Heights",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01106651"
    },
    {
      "nct_id": "NCT04586985",
      "title": "Safety, Tolerability and Pharmacokinetics of FTX-6058",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Adult Subjects",
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "FTX-6058/placebo oral capsule(s)",
          "type": "DRUG"
        },
        {
          "name": "FTX-6058 - Two Dosing Periods",
          "type": "DRUG"
        },
        {
          "name": "FTX-6058 / Midazolam Syrup",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fulcrum Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 109,
      "start_date": "2020-10-26",
      "completion_date": "2022-11-15",
      "has_results": false,
      "last_update_posted_date": "2022-12-12",
      "last_synced_at": "2026-10-05T08:38:13.606Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • Overland Park, Kansas",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04586985"
    }
  ]
}